CAS: 3972-25-6; Tert-Butanol-D

相似化合物

925-93-9 3979-51-9

上下游产品

CAS号556-91-2 叔丁醇铝 | CAS号75-65-0 叔丁醇 | CAS号865-48-5 叔丁醇钠 | CAS号3141-58-0 tert-butoxy | CAS号14976-54-6 trans-di-tert-b... | CAS号1634-04-4 甲基叔丁基醚 | CAS号540-88-5 醋酸叔丁酯 | CAS号811-98-3 氘代甲醇 | CAS号13537-03-6 膦-d3 | CAS号13587-50-3 protiophosphane | CAS号13780-29-5 dideuteriophosphane | CAS号7803-51-2 磷化氢 | CAS号1449-63-4 trimethylgermane | CAS号865-52-1 四甲基锗 | CAS号1066-63-3 dimethylgermani... | CAS号558-30-5 甲基环氧丙烷 | CAS号67-64-1 丙酮

叔丁基过氧化氢置于苯甲醛-α-D1,4,4'-二溴-2,2'-联吡啶,Copper(L) Chloride体系中,用 乙腈 用作溶剂,化学反应 24.0H,反应生成氘代叔丁醇
参考文献:铜通过分子内自由基级联酰基氰化反应合成含cn的苯并二氢吡喃-4-酮
标题:铜通过分子内自由基级联酰基氰化反应合成含cn的苯并二氢吡喃-4-酮
摘要:已经开发了铜催化的分子内自由基级联酰基氰化以合成含氰基的chroman-4-Ones.使用绿色氰基源,在温和的条件下,可以中等到非常好的收率制备一系列cn取代的chroman-4-One衍生物.对照实验表明该反应涉及分子内酰基自由基加成/氰化过程.此外,该协议具有步长和原子经济性,将氰基引入到chroman-4-One中引起了极大的兴趣和重要性.
Doi:10.1016/j.Tetlet.2021.153061

专利信息

专利号:US-8952207-B2
优先权日:2007-09-11
标题:Copper-catalyzed C—H bond arylation
发明人：DAUGULIS OLAFS; DO HIEN-QUANG
权利人:DAUGULIS OLAFS; DO HIEN-QUANG; UNIV HOUSTON SYSTEM
摘要:The present invention is a one-step method for efficiently converting carbon-hydrogen bonds into carbon-carbon bonds using a combination of aryl halides, a substrate, and a copper salt as catalyst. This method allows faster introduction of complex molecular entities, a process that would otherwise require many more steps. This invention is particularly relevant for the organic synthesis of complex molecules such as, but not limited to, pharmacophores and explosives.

专利号:US-11078153-B2
优先权日:2019-04-03
标题:2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase
发明人：SILVERMAN RICHARD B
权利人:UNIV NORTHWESTERN
摘要:Disclosed are enantiomerically pure cyclopentane-based compounds that are prepared by a multiple-step synthesis process. The disclosed compounds have been designed to inhibit gamma-aminobutyric acid-amino transferase (GABA-AT) activity and ornithine aminotransferase (OAT) activity. Some of the enantiomerically pure compounds inhibit OAT activity more potently than the racemic compound. The disclosed compounds may be used to selectively inhibit OAT activity, for example, to treat hepatocellular carcinoma and/or used to selected inhibit GABA-AT activity, for example, to treat neurological diseases and disorders.